In the pharmacological management of heavy menstrual bleeding, all of the following are evidence-based first-line medical options EXCEPT:

Explanation

## First-Line Medical Management of Heavy Menstrual Bleeding ### Evidence-Based First-Line Options **Key Point:** The FIGO and WHO guidelines recommend four main first-line pharmacological options for heavy menstrual bleeding in women seeking medical (non-surgical) management. [cite:FIGO 2018, WHO MEC 2015] ### Established First-Line Agents | Agent | Mechanism | Efficacy | Notes | |---|---|---|---| | **LNG-IUS** | Local progestin, endometrial suppression | 80–90% reduction in menstrual blood loss | Most effective; requires insertion | | **COCPs** | Endometrial suppression, cycle regulation | 40–50% reduction | Convenient, multiple benefits; contraindications exist | | **Tranexamic Acid** | Antifibrinolytic; inhibits plasminogen activation | 40–50% reduction | Taken during menses only; good safety profile | | **NSAIDs** (e.g. mefenamic acid) | Inhibit prostaglandin synthesis | 20–30% reduction | Modest effect; GI side effects | ### Why Estrogen-Progestin Patches Are NOT First-Line **High-Yield:** Transdermal estrogen-progestin patches (e.g. ethinyl estradiol/norelgestromin) are **not** recommended as first-line therapy for heavy menstrual bleeding. They are: - Not specifically formulated or studied for menorrhagia management - Less effective than COCPs (which deliver higher endometrial suppression) - Primarily indicated for contraception, not AUB treatment - Not included in FIGO or WHO first-line recommendations for HMB **Clinical Pearl:** If hormonal therapy is chosen, **oral** combined contraceptives (COCPs) are preferred over transdermal patches for AUB because the oral route achieves better endometrial suppression and has stronger evidence in the menorrhagia literature. ### Treatment Algorithm ```mermaid flowchart TD A[Heavy Menstrual Bleeding]:::outcome --> B{Structural pathology?}:::decision B -->|Yes| C[Treat underlying cause]:::action B -->|No| D{Desires contraception?}:::decision D -->|Yes| E[LNG-IUS or COCP]:::action D -->|No| F[Tranexamic acid or NSAIDs]:::action E --> G[Reassess at 3 months]:::action F --> G G --> H{Adequate response?}:::decision H -->|Yes| I[Continue]:::outcome H -->|No| J[Add second agent or consider surgery]:::action ``` ### Mnemonic for First-Line Options **"LACE"** — **L**NG-IUS, **A**ntifibrinolytic, **C**OCP, **E**ndometrial ablation (second-line surgical) [cite:FIGO 2018 Menstrual Disorders; WHO MEC 2015]